The Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy.
As the largest conference solely focused on cancer immunotherapy, the Annual Meeting & Pre-Conference Programs provides more than 3,500 international leaders from academia, regulatory and government agencies, as well as industry representatives with a multidisciplinary educational and interactive environment focused on improving outcomes for all cancer patients.
SITC is excited to welcome delegates to the 33rd Annual Meeting & Pre-Conference Programs (SITC 2018) on Nov. 7 – 11, 2018 at the Walter E. Washington Convention Center in Washington, D.C.
Registration for SITC 2018 is now open to the general public! Join SITC at the leading destination for scientific exchange, education and networking in the cancer immunotherapy field.
Become a SITC member today so you can gain access to discounted SITC 2018 registration rates and many more membership benefits!
Learn from past delegates why you cannot miss the SITC Annual Meeting & Pre-Conference Programs in the following videos:
Looking for archived SITC Annual Meeting content? Visit past conference websites below:
The following are future scheduled dates and locations for the society's Annual Meeting & Pre-Conference Programs:
Nov. 7-11, 2018 at the Walter E. Washington Convention Center
Nov. 6-10, 2019 at the Gaylord National Hotel & Convention Center
National Harbor, Maryland
Nov. 11-15, 2020 at the Gaylord National Hotel & Convention Center
National Harbor, Maryland
Nov. 10-14, 2021 at the Walter E. Washington Convention Center
Join SITC members, Drs. Vincenzo Bronte, Lorenzo Galluzzi and Jérôme Galon, for the Primer on Cancer Immunology and Immunotherapy at the International Conference on Immunotherapy Radiotherapy Combinations Sept. 20–22 in Paris. Attention SITC members! ...
This two day program is divided into a lectures series presented by world class scientists in the field of immuno-oncology, and a hands-on workshop laboratory to explore the optimization and troubleshooting of Opal staining, multispectral image acquisition ...
Currently scfvs, antibody-derived single chain variable fragment based CAR to target CD19 antigen is the most common CAR strategy clinically used. But based on the cited article, tumor cells can be targeted also through use of non-antibody based approahes.This ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com